Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Abivax American Depositary Shares ABVX

Healthcare Biotechnology
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ABVX)

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

GlobeNewswire November 19, 2024

Abivax presents third quarter 2024 key financial information

GlobeNewswire November 14, 2024

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

GlobeNewswire November 13, 2024

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

GlobeNewswire October 7, 2024

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

GlobeNewswire October 3, 2024

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

GlobeNewswire October 3, 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

GlobeNewswire September 26, 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

GlobeNewswire September 25, 2024

Abivax presents first-half 2024 financial results

GlobeNewswire September 9, 2024
View More News ››

Opinion & Analysis (NDAQ:ABVX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ABVX)

(ABVX) Technical Pivots with Risk Controls

BREAKING NEWS: $ABVX (ABVX) Technical Pivots with Risk Controls2024-11-17 18:28:00 ET Stock Traders Daily has produced this trading...
whytestocks - November 17, 2024
View more Bullboard ››

Laurion Mineral Exploration Inc.

Laurion Mineral Exploration Inc.

Laurion Mineral Exploration Inc. is a Canada-based mid-stage junior exploration and development company. The Company is ...
View More »